Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18915144 | READY-TO-USE SODIUM PHOSPHATES INJECTION | October 2024 | February 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18730659 | SINGLE-DOSE COSMETIC PRODUCT AND PROCESS OF MANUFACTURING THEREOF | July 2024 | February 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 18667826 | READY-TO-USE SODIUM PHOSPHATES INJECTION | May 2024 | July 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18653070 | METHODS FOR SHRINKING PITUITARY TUMORS | May 2024 | March 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18645654 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | April 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18639748 | COMPOSITION COMPRISING OIL PALM PHENOLICS FOR USE IN THE TREATMENT AND PREVENTION OF COLON DISEASES AND FOR PROMOTING AND MAINTAINING GUT AND GENERAL HEALTH | April 2024 | March 2025 | Allow | 11 | 1 | 0 | Yes | No |
| 18628073 | HIGHLY CRYSTALLINE ALPHA-1,3-GLUCAN | April 2024 | February 2025 | Allow | 10 | 1 | 0 | No | No |
| 18606860 | THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONS | March 2024 | March 2025 | Allow | 12 | 2 | 0 | No | No |
| 18589336 | Compositions, Kits, Methods and Uses for Cleaning, Disinfecting, Sterilizing and/or Treating | February 2024 | March 2025 | Allow | 13 | 2 | 0 | No | No |
| 18441673 | METHODS OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS VIA ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMIN | February 2024 | February 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18436480 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | February 2024 | December 2024 | Allow | 10 | 1 | 0 | No | No |
| 18436682 | DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF | February 2024 | November 2024 | Allow | 9 | 1 | 0 | No | No |
| 18431234 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | February 2024 | December 2024 | Allow | 10 | 1 | 0 | No | No |
| 18405634 | HYDROGELS AS RHEOLOGY MODIFIERS AND METHODS OF MAKING THE SAME | January 2024 | November 2024 | Allow | 11 | 1 | 0 | No | No |
| 18403406 | 2-OXO-2-({2-[(PHENYLCARBAMOYL)OXY]ETHYL}AMINO)ETHYL PHENYLCARBAMATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | January 2024 | May 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18538903 | IMPLANT WITH FILLABLE RESERVOIR | December 2023 | April 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18379505 | BALLOON CATHETERS FOR BODY LUMENS | October 2023 | August 2024 | Allow | 11 | 1 | 0 | No | No |
| 18379190 | DERMAL FILLERS AND APPLICATIONS THEREOF | October 2023 | May 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18376044 | METHODS AND COMPOSITIONS FOR WOUND HEALING | October 2023 | August 2024 | Allow | 10 | 1 | 0 | No | No |
| 18372657 | NANO-SIZED MIXED LIGAND [4-BROMO-2-(QUINOLIN-2-YLIMINOMETHYL)-PHENOL IMINE- PHENANTHROLINE] RU(III) COMPLEX FOR MEDICINAL APPLICATIONS | September 2023 | December 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18362431 | NOVEL ORAL LIQUID COMPOSITIONS OF ENZALUTAMIDE AND METHOD OF MANUFACTURING THEREOF | July 2023 | August 2024 | Allow | 12 | 1 | 1 | No | No |
| 18220371 | COMPOSITIONS AND METHODS FOR TREATING INTERVERTEBRAL DISCS | July 2023 | June 2024 | Allow | 12 | 2 | 0 | Yes | No |
| 18219837 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | July 2023 | March 2025 | Allow | 20 | 2 | 0 | No | No |
| 18345683 | Multi-Functional Hemocompatible Porous Bead Sorbent For Removing Protein Based Toxins And Potassium From Biological Fluids | June 2023 | September 2024 | Allow | 15 | 1 | 0 | No | No |
| 18214131 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | June 2023 | June 2024 | Allow | 11 | 1 | 0 | No | No |
| 18329841 | Adhesive Containing Microparticles | June 2023 | April 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18205283 | PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLSULFONAMIDES, AND THEIR THERAPEUTIC APPLICATIONS | June 2023 | September 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18201709 | AMTIMICROBIAL SILICONES | May 2023 | August 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18315448 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | May 2023 | March 2024 | Allow | 11 | 1 | 0 | No | No |
| 18138583 | ZINC OXIDE PARTICLES, PHOTOSTABLE UV FILTERS, AND METHODS OF USE THEREOF | April 2023 | May 2024 | Allow | 12 | 1 | 0 | No | No |
| 18123630 | GREEN SYNTHESIS OF SILVER NANOPARTICLES USING EUPHORBIA DENDROIDES AQUEOUS EXTRACT | March 2023 | August 2023 | Allow | 5 | 0 | 1 | No | No |
| 18184845 | HIGHLY CRYSTALLINE ALPHA-1,3-GLUCAN | March 2023 | February 2024 | Allow | 11 | 1 | 0 | No | No |
| 18117174 | Novel Retenoic Acid Esters | March 2023 | December 2023 | Abandon | 9 | 1 | 0 | No | No |
| 18117152 | Novel Retinoates | March 2023 | December 2023 | Abandon | 10 | 2 | 0 | No | No |
| 18112636 | TWO-STAGE MICROPARTICLE-BASED THERAPEUTIC DELIVERY SYSTEM AND METHOD | February 2023 | November 2024 | Abandon | 20 | 1 | 1 | No | No |
| 18170246 | THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION | February 2023 | January 2024 | Allow | 11 | 1 | 0 | No | No |
| 18109328 | DEPOT SYSTEMS COMPRISING CARIPRAZINE OR SALTS THEREOF | February 2023 | November 2023 | Allow | 9 | 1 | 0 | Yes | No |
| 18163060 | COMPOSITIONS, SYSTEMS, AND METHODS FOR ORAL DELIVERY | February 2023 | June 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18099147 | NON-WINTERIZED, STANDARDIZED MARINE SOURCE OIL PRODUCTS AND METHODS OF MAKING THEREOF | January 2023 | January 2024 | Allow | 12 | 1 | 0 | No | No |
| 18098370 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | January 2023 | December 2023 | Allow | 11 | 2 | 0 | No | No |
| 18097698 | BALLOON CATHETERS FOR BODY LUMENS | January 2023 | July 2023 | Allow | 6 | 1 | 0 | No | No |
| 18097690 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | January 2023 | June 2023 | Allow | 5 | 1 | 0 | No | No |
| 18074577 | Skin Care Composition | December 2022 | March 2024 | Abandon | 16 | 1 | 1 | No | No |
| 18071110 | CLEVIDIPINE NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS THEREOF | November 2022 | April 2025 | Allow | 29 | 2 | 1 | Yes | No |
| 17992715 | ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF | November 2022 | December 2023 | Allow | 12 | 2 | 0 | No | No |
| 17992707 | THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONS | November 2022 | November 2023 | Allow | 12 | 2 | 0 | No | No |
| 17992703 | THERAPEUTIC USES FOR SODIUM THIOSULFATE FORMULATIONS | November 2022 | November 2023 | Allow | 12 | 2 | 0 | No | No |
| 18056387 | LONG ACTING GASTRIC RESIDENCE SYSTEM | November 2022 | October 2023 | Allow | 11 | 1 | 0 | No | No |
| 17967259 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | October 2022 | November 2023 | Allow | 13 | 1 | 0 | No | No |
| 17951321 | DRUG COATED BALLOON CATHETERS FOR NONVASCULAR STRICTURES | September 2022 | October 2023 | Allow | 12 | 1 | 0 | No | No |
| 17947058 | METHOD FOR CONTINUOUS FABRICATION OF MULTI-FUNCTIONAL NANOGELS | September 2022 | January 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 17944259 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | September 2022 | November 2023 | Allow | 14 | 1 | 0 | No | No |
| 17823120 | METHODS OF USING POLYMERS | August 2022 | December 2024 | Allow | 28 | 3 | 0 | Yes | No |
| 17799754 | COSMETIC COMPOSITIONS CONTAINING LOW MOLECULAR WEIGHT AMORPHOUS GRADE POLYLACTIC ACID RESIN | August 2022 | June 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17760125 | COMPOSITION FOR RESTORATION OF TISSUE INCLUDING BIODEGRADABLE POLYMERIC COPOLYMER | August 2022 | May 2025 | Allow | 34 | 1 | 0 | No | No |
| 17816008 | HERBAL SHAMPOO COMPOSITION AND METHOD FOR PREPARING THE SAME | July 2022 | December 2022 | Allow | 5 | 1 | 0 | No | No |
| 17874412 | Non-Greasy Personal Care Compositions | July 2022 | January 2024 | Allow | 17 | 1 | 0 | No | No |
| 17873818 | SINGLE-DOSE, READY-TO-USE INJECTABLE FORMULATIONS | July 2022 | July 2023 | Allow | 12 | 0 | 0 | No | No |
| 17867252 | AMTIMICROBIAL SILICONES | July 2022 | March 2023 | Allow | 8 | 0 | 1 | Yes | No |
| 17811026 | ORAL ELIGLUSTAT TRANSMUCOSAL DELIVERY SYSTEM | July 2022 | June 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17849893 | Method of making an osteoconductive polymer article and an osteoconductive polymer article thus made | June 2022 | March 2024 | Allow | 21 | 1 | 0 | No | No |
| 17843208 | BALLOON CATHETERS FOR BODY LUMENS | June 2022 | July 2023 | Allow | 13 | 1 | 0 | No | No |
| 17843150 | DRUG-COATED BALLOON CATHETERS FOR BODY LUMENS | June 2022 | June 2024 | Allow | 24 | 2 | 0 | No | No |
| 17833658 | Extracellular Matrix for Treating Pelvic Floor Disorders and Skeletal Muscle Degeneration | June 2022 | June 2023 | Allow | 12 | 1 | 0 | No | No |
| 17825197 | HYDROGELS AS RHEOLOGY MODIFIERS AND METHODS OF MAKING THE SAME | May 2022 | October 2023 | Allow | 16 | 1 | 0 | No | No |
| 17776048 | DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION | May 2022 | April 2025 | Allow | 35 | 1 | 0 | No | No |
| 17739037 | ANTERIOR SEGMENT DRUG DELIVERY | May 2022 | August 2024 | Allow | 27 | 0 | 0 | No | No |
| 17774203 | BAKED CONFECTION | May 2022 | May 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17763174 | METHODS AND FORMULATIONS FOR CROSSLINKING HAIR OR OTHER KERATIN FIBERS USING OXIDIZED SUGARS AS CROSSLINKING AGENTS | March 2022 | March 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17753841 | AGROCHEMICAL FORMULATION CONTAINING A SULFOPOLYMER | March 2022 | June 2025 | Allow | 39 | 1 | 0 | No | No |
| 17654786 | Compositions, Kits, Methods and Uses for Cleaning, Disinfecting, Sterilizing and/or Treating | March 2022 | October 2023 | Allow | 19 | 2 | 0 | No | No |
| 17641093 | PLUNGER FOR A SYRINGE-TYPE PUMP FOR A MACHINE FOR ENCAPSULATION OF SOFT CAPSULES, AND SYRINGE-TYPE PUMP COMPRISING ONE OR MORE OF SAID PLUNGERS | March 2022 | December 2024 | Allow | 34 | 0 | 0 | No | No |
| 17679995 | IMPLANT WITH FILLABLE RESERVOIR | February 2022 | September 2023 | Allow | 19 | 0 | 0 | Yes | No |
| 17673008 | ANTIMICROBIAL INSERTS FOR MEDICAL DEVICES | February 2022 | February 2025 | Allow | 36 | 1 | 0 | No | No |
| 17562282 | REACTIVE DRY POWDERED HEMOSTATIC MATERIALS COMPRISING A PROTEIN AND A MULTIFUNCTIONALIZED MODIFIED POLYETHYLENE GLYCOL BASED CROSSLINKING AGENT | December 2021 | July 2024 | Allow | 31 | 1 | 1 | No | No |
| 17622392 | BIODEGRADABLE RESIN PARTICLES AND EXTERNAL PREPARATION INCLUDING THE SAME | December 2021 | July 2024 | Allow | 31 | 0 | 0 | Yes | No |
| 17596413 | USE OF ABELMOSCHI COROLLA EXTRACT IN PREPARATION OF DRUG FOR TREATING FIBROSIS | December 2021 | May 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17545886 | COSMETIC COMPOSITION COMPRISING A HYDROXYALKYL STARCH AS MAIN EMULSIFYING SYSTEM | December 2021 | December 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17537789 | OIL-IN-WATER TYPE EMULSIFIED COSMETIC | November 2021 | April 2023 | Allow | 17 | 0 | 0 | Yes | No |
| 17535102 | IMPLANTS HAVING A DRUG LOAD OF AN OXYSTEROL AND METHODS OF USE | November 2021 | July 2024 | Allow | 32 | 2 | 1 | No | No |
| 17534415 | THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF MITOTIC KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR | November 2021 | February 2023 | Allow | 14 | 1 | 0 | No | No |
| 17531658 | BIOERODIBLE IMPLANT FOR LONG-TERM DRUG DELIVERY AND ASSOCIATED METHODS OF MANUFACTURE AND USE | November 2021 | July 2023 | Allow | 20 | 1 | 0 | No | No |
| 17612945 | OXYGENATED CANNABIS SKIN THERAPY COMPOSITIONS AND METHODS FOR PRODUCING THE COMPOSITIONS | November 2021 | March 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17525074 | METHODS OF REPELLING BITING ARTHROPODS, REDUCING PATHOGEN SPREAD AND TREATING ARTHROPOD INFESTATION | November 2021 | June 2023 | Allow | 19 | 1 | 0 | No | No |
| 17524467 | FORMULATIONS FOR ORAL DELIVERY OF ADSORBENTS IN THE GUT | November 2021 | December 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17609601 | AN HERBO-MINERAL COMPOSITION FOR ALLEVIATING ADVERSE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS | November 2021 | October 2024 | Allow | 35 | 0 | 0 | Yes | No |
| 17518157 | Implantable Materials and Uses Thereof | November 2021 | March 2025 | Abandon | 40 | 0 | 2 | No | No |
| 17499534 | Self-Emulsifying Bioactive Concentrates | October 2021 | December 2022 | Allow | 14 | 1 | 0 | Yes | No |
| 17594130 | METHODS AND COMPOSITIONS FOR PROMOTING HEALTH IN A SUBJECT | October 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17489915 | SYNERGISTIC COMPOSITION FOR OSTEOARTHRITIS | September 2021 | September 2024 | Allow | 36 | 1 | 0 | No | No |
| 17488720 | IRON-FORTIFIED FOOD COMPOSITION | September 2021 | October 2022 | Allow | 13 | 0 | 0 | No | No |
| 17599247 | Method of extracting caffeic acid and rosemarinic acid from rosemary | September 2021 | December 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17486225 | PHARMACEUTICAL FORMULATION | September 2021 | March 2025 | Allow | 42 | 3 | 1 | No | No |
| 17449082 | Arthropod Pest Control Compositions, Kits and Uses Thereof | September 2021 | November 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17480687 | SYNERGISTIC ANTIOXIDANT COSMETIC COMPOSITION CONTAINING AT LEAST ONE HYDROXYTYROSOL AND AT LEAST ONE SULFORAPHANE | September 2021 | October 2023 | Allow | 24 | 1 | 0 | Yes | No |
| 17441573 | METHOD FOR EXTRACTING GYMNADENIA CONOPSEA AND RELATED GYMNADENIA CONOPSEA EXTRACT | September 2021 | April 2024 | Allow | 31 | 0 | 0 | Yes | No |
| 17440355 | HIGH OIL CONTENT TOPICAL PERSONAL CARE PRODUCTS | September 2021 | November 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17469385 | Biomedical Foams | September 2021 | October 2023 | Allow | 25 | 2 | 0 | Yes | No |
| 17410538 | MASKING SPRAY | August 2021 | December 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17402473 | FLOWABLE COLLAGEN COLLOID AND METHOD OF FORMING | August 2021 | November 2024 | Abandon | 40 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LAZARO, DOMINIC.
With a 24.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LAZARO, DOMINIC works in Art Unit 1611 and has examined 659 patent applications in our dataset. With an allowance rate of 61.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner LAZARO, DOMINIC's allowance rate of 61.5% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LAZARO, DOMINIC receive 2.27 office actions before reaching final disposition. This places the examiner in the 77% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by LAZARO, DOMINIC is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +37.0% benefit to allowance rate for applications examined by LAZARO, DOMINIC. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.6% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 34.8% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 54.5% of appeals filed. This is in the 20% percentile among all examiners. Of these withdrawals, 36.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 51.7% are granted (fully or in part). This grant rate is in the 64% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 48% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.